Evidence map›Paper›PMID 38164185›Full record

ArticleInternational journal of biological sciences2024

MRCK as a Potential Target for Claudin-Low Subtype of Breast Cancer.

Hirohito Yamaguchi, Ling-Chu Chang, Olin Shih-Shin Chang, Yu-Fu Chen, Yu-Chun Hsiao, Chen-Shiou Wu, Mien-Chie Hung

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Hirohito YamaguchiGraduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
Ling-Chu ChangCenter for Molecular Medicine, China Medical University Hospital, Taichung City 40402, Taiwan R.O.C.
Olin Shih-Shin ChangDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yu-Fu ChenGraduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
Yu-Chun HsiaoGraduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
Chen-Shiou WuGraduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
Mien-Chie HungGraduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
China Medical University · TWChina Medical University Hospital · TWThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To find new molecular targets for triple negative breast cancer (TNBC), we analyzed a large-scale drug screening dataset based on breast cancer subtypes. We discovered that BDP-9066, a specific MRCK inhibitor (MRCKi), may be an effective drug against TNBC. After confirming the efficacy and specificity of BDP-9066 against TNBC

Indexed as

Adaptor Proteins, Signal TransducingTriple Negative Breast NeoplasmsCell Line, TumorClaudinsHumansPhosphatidylinositol 3-KinasesTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingClaudinsPhosphatidylinositol 3-KinasesTranscription FactorsYAP-Signaling ProteinsClaudin-lowFocal adhesionsMRCKp65TNBCYAP/TAZ

Identifiers

PMID38164185
PMCPMC10750295
OpenAlexW4388028149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.